[go: up one dir, main page]

FI20011478A0 - Farmaseuttinen koostumus - Google Patents

Farmaseuttinen koostumus

Info

Publication number
FI20011478A0
FI20011478A0 FI20011478A FI20011478A FI20011478A0 FI 20011478 A0 FI20011478 A0 FI 20011478A0 FI 20011478 A FI20011478 A FI 20011478A FI 20011478 A FI20011478 A FI 20011478A FI 20011478 A0 FI20011478 A0 FI 20011478A0
Authority
FI
Finland
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
FI20011478A
Other languages
English (en)
Swedish (sv)
Other versions
FI20011478L (fi
FI117667B (fi
Inventor
Myoeh Ilm
Original Assignee
Inion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inion Ltd filed Critical Inion Ltd
Priority to FI20011478A priority Critical patent/FI117667B/fi
Publication of FI20011478A0 publication Critical patent/FI20011478A0/fi
Priority to CA002387981A priority patent/CA2387981A1/en
Priority to US10/189,302 priority patent/US7041645B2/en
Priority to EP02396115A priority patent/EP1273303A1/en
Priority to MXPA02006679A priority patent/MXPA02006679A/es
Publication of FI20011478L publication Critical patent/FI20011478L/fi
Priority to US11/346,673 priority patent/US7358227B2/en
Application granted granted Critical
Publication of FI117667B publication Critical patent/FI117667B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI20011478A 2001-07-05 2001-07-05 Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä FI117667B (fi)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FI20011478A FI117667B (fi) 2001-07-05 2001-07-05 Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
CA002387981A CA2387981A1 (en) 2001-07-05 2002-06-25 Pharmaceutical composition
US10/189,302 US7041645B2 (en) 2001-07-05 2002-07-02 Methods of inhibiting or inducing bone formation
EP02396115A EP1273303A1 (en) 2001-07-05 2002-07-04 Pharmaceutical composition comprising a mixture of at least two rBMPs and the use thereof in the treatment of orthopaedic and dental patients
MXPA02006679A MXPA02006679A (es) 2001-07-05 2002-07-04 Composicion farmaceutica.
US11/346,673 US7358227B2 (en) 2001-07-05 2006-02-03 Pharmaceutical compositions comprising bone morphogenetic protein monomers for inhibiting bone formation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20011478 2001-07-05
FI20011478A FI117667B (fi) 2001-07-05 2001-07-05 Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä

Publications (3)

Publication Number Publication Date
FI20011478A0 true FI20011478A0 (fi) 2001-07-05
FI20011478L FI20011478L (fi) 2003-01-06
FI117667B FI117667B (fi) 2007-01-15

Family

ID=8561603

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20011478A FI117667B (fi) 2001-07-05 2001-07-05 Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä

Country Status (5)

Country Link
US (2) US7041645B2 (fi)
EP (1) EP1273303A1 (fi)
CA (1) CA2387981A1 (fi)
FI (1) FI117667B (fi)
MX (1) MXPA02006679A (fi)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI116827B (fi) 2001-08-24 2006-03-15 Univ Zuerich Luun morfogeneettisen proteiinin deleetiomutantti, sitä sisältävä farmaseuttinen koostumus ja sen käyttö
US7309232B2 (en) * 2003-10-10 2007-12-18 Dentigenix Inc. Methods for treating dental conditions using tissue scaffolds
US10059756B2 (en) * 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
MX2009004718A (es) 2006-11-02 2009-06-19 Acceleron Pharma Inc Antagonistas de receptor de alk1 y ligando y sus usos.
EP2160401B1 (en) 2007-05-11 2014-09-24 Altor BioScience Corporation Fusion molecules and il-15 variants
US8133553B2 (en) 2007-06-18 2012-03-13 Zimmer, Inc. Process for forming a ceramic layer
US8309521B2 (en) 2007-06-19 2012-11-13 Zimmer, Inc. Spacer with a coating thereon for use with an implant device
US8608049B2 (en) 2007-10-10 2013-12-17 Zimmer, Inc. Method for bonding a tantalum structure to a cobalt-alloy substrate
US9688735B2 (en) * 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
US10774132B2 (en) * 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
US9301971B2 (en) * 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
WO2014197535A1 (en) * 2013-06-04 2014-12-11 Virginia Commonwealth University Recombinant cancer therapeutic cytokine
JP6509852B2 (ja) * 2013-07-31 2019-05-08 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）の構築物
US11072647B2 (en) * 2013-12-19 2021-07-27 Onsejo Nacional DE Investigation Cientiticay Tecnica TGF-receptor II isoform, fusion peptide, methods of treatment and methods in vitro
PL3160498T3 (pl) 2014-06-30 2022-02-21 Altor Bioscience Corporation Cząsteczki na bazie IL-15 i sposoby ich zastosowania
GB201412290D0 (en) 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
SG10201802098UA (en) * 2014-07-30 2018-04-27 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
CN115043945A (zh) 2014-10-31 2022-09-13 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
ITMI20150558A1 (it) * 2015-04-16 2016-10-16 Univ Politecnica Delle Marche Irisina per la cura e la prevenzione dell'osteoporosi
JP6598036B2 (ja) * 2015-05-20 2019-10-30 国立大学法人大阪大学 炎症性サイトカイン分泌抑制活性を有するオリゴペプチド
US11571462B2 (en) * 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
AU2016271292B2 (en) * 2015-06-03 2022-04-14 The Medical College Of Wisconsin, Inc. An engineered CCL20 locked dimer polypeptide
CA2998390A1 (en) * 2015-09-28 2017-04-06 East Carolina University Aluminum based adjuvants for tolerogenic vaccination
US11230583B2 (en) * 2015-11-26 2022-01-25 Hudson Institute of Medical Research Inhibin analogs
JP6946304B2 (ja) * 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
WO2017176938A1 (en) * 2016-04-06 2017-10-12 Acceleron Pharma, Inc. Bmprii polypeptides and uses thereof
SI3496739T1 (sl) * 2016-07-15 2021-06-30 Acceleron Pharma Inc. Sestave, ki zajemajo polipeptide actriia, za uporabo pri zdravljenju pljučne hipertenzije
WO2018018082A1 (en) * 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Polypeptides derived from CSF-m and their uses
WO2018187209A1 (en) * 2017-04-03 2018-10-11 Acceleron Pharma Inc. Compositions and methods for treating spinal muscular atrophy
WO2019106592A2 (en) * 2017-11-30 2019-06-06 Grifols Diagnostic Solutions Inc. Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors pd1 and pd-l1
TWI724392B (zh) * 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
EP3553081A1 (en) * 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Atrial natriuretic peptide engrafted antibodies
EP3553082A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Brain natriuretic peptide engrafted antibodies
KR102873899B1 (ko) * 2018-06-22 2025-10-20 큐진 인크. 인터루킨-2 변이체 및 이의 사용 방법
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
US12105097B2 (en) * 2019-01-27 2024-10-01 China Medical University Rheumatoid arthritis auto-antibody-bound peptide and application thereof
JP7754723B2 (ja) * 2019-05-14 2025-10-15 ウェアウルフ セラピューティクス， インコーポレイテッド 分離部分及びその使用方法
CN120795117A (zh) * 2019-06-14 2025-10-17 科优基因公司 用于癌症治疗的新型白介素-2变体
US11851490B2 (en) * 2019-08-15 2023-12-26 Northwestern University Methods and compositions for treating, inhibiting, and/or preventing heterotopic ossification
MX2022002638A (es) * 2019-09-06 2022-03-25 Novartis Ag Proteinas de fusion terapeuticas.
AU2020394255A1 (en) * 2019-11-26 2022-06-09 Yuhan Corporation Long-acting GDF15 fusion protein and pharmaceutical composition comprising same
KR20220122648A (ko) * 2019-12-03 2022-09-02 차이나 메디칼 유니버시티 올리고펩티드, 이의 테스트 키트, 및 이의 의약 조성물
WO2021123173A1 (en) * 2019-12-20 2021-06-24 F. Hoffmann-La Roche Ag Il-37 fusion proteins and uses thereof
CA3164910A1 (en) * 2020-01-23 2021-07-29 Young Chul Sung Fusion protein comprising pd-l1 protein and use thereof
CA3185618A1 (en) * 2020-06-04 2021-12-09 Medical Research & Development Fund for Health Services Bnai Zion Medical Center Modified semaphorin 3a, compositions comprising the same and uses thereof
ES2950137T3 (es) * 2020-09-24 2023-10-05 Gubra Aps Análogos de hAM15-52 con potencia mejorada frente al receptor de amilina (hAMY3R)
IL302276A (en) 2020-10-23 2023-06-01 Asher Biotherapeutics Inc Fusions with cd8 antigen binding molecules for modulating immune cell function
AU2021414400A1 (en) * 2020-12-31 2023-08-17 Innate Pharma Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123
TW202313095A (zh) * 2021-05-17 2023-04-01 美商再生元醫藥公司 用於治療血管新生眼疾之延長、高劑量vegf拮抗劑方案
AU2022275666A1 (en) * 2021-05-19 2023-12-07 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563489A (en) 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
US5631142A (en) 1986-07-01 1997-05-20 Genetics Institute, Inc. Compositions comprising bone morphogenetic protein-2 (BMP-2)
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
AU651421B2 (en) 1990-11-30 1994-07-21 Celtrix Pharmaceuticals, Inc. Use of a bone morphogenetic protein in synergistic combination with TGF-beta for bone repair
KR100259827B1 (ko) 1991-11-04 2000-06-15 브루스 엠. 에이센, 토마스 제이 데스로저 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법
US5399677A (en) 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
US6180606B1 (en) 1994-09-28 2001-01-30 Gensci Orthobiologics, Inc. Compositions with enhanced osteogenic potential, methods for making the same and uses thereof
US6048964A (en) * 1995-12-12 2000-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
AU3269399A (en) 1999-03-22 2000-10-09 Universitat Zurich Transforming growth factor (tfg) beta superfamily antagonists
WO2000064460A2 (en) 1999-04-23 2000-11-02 Sulzer Orthopedics Ltd. Composition for enhancing functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin

Also Published As

Publication number Publication date
US20030045474A1 (en) 2003-03-06
EP1273303A1 (en) 2003-01-08
US20060147534A1 (en) 2006-07-06
CA2387981A1 (en) 2003-01-05
FI20011478L (fi) 2003-01-06
FI117667B (fi) 2007-01-15
US7041645B2 (en) 2006-05-09
MXPA02006679A (es) 2005-12-19
US7358227B2 (en) 2008-04-15

Similar Documents

Publication Publication Date Title
FI20011478A0 (fi) Farmaseuttinen koostumus
PL367180A1 (pl) Trwała kompozycja farmaceutyczna
EE200300416A (et) Ravimvorm
DK1524266T3 (da) Farmaceutisk sammensætning
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
FI20105657L (fi) Farmaseuttisia koostumuksia
NO20033556L (no) Farmasöytiske formuleringer
NO20033384L (no) Farmasoytisk formulering
ITMI20010748A0 (it) Composizioni farmaceutiche
DK1395242T3 (da) Flydende farmaceutisk sammensætning
BR0210619A (pt) composição
EE200300589A (et) Ravimkoostised
NO20035627D0 (no) Farmasöytisk formulering
FI20022128L (fi) Farmaseuttinen koostumus
NO20026123L (no) Farmasöytiske sammensetninger
NO20031095L (no) Farmasoytiske sammensetninger
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE10291905D2 (de) Pharmazeutische Zusammensetzung
DE10107261B4 (de) Pharmazeutische Zusammensetzung
EP1413314A4 (en) MEDICAL COMPOSITIONS
EE200200689A (et) Ravimkoostised
FI5468U1 (fi) Farmaseuttinen koostumus
SE0100847D0 (sv) Novel pharmaceutical composition
NO20041236L (no) Farmasoytisk formulering
SE0103116D0 (sv) Pharmaceutical combination

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 117667

Country of ref document: FI